Silpa Nuthalapati, Ph.D.
Affiliations: | 2012 | Pharmaceutical Sciences | Temple University, Philadelphia, PA, United States |
Area:
Pharmacy, Pharmacology, OncologyGoogle:
"Silpa Nuthalapati"Parents
Sign in to add mentor| Daniel J. Canney | grad student | 2012 | Temple University | |
| (Preclinical pharmacokinetic and pharmacodynamic evaluation of new anticancer agents for brain tumor chemotherapy.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| LoRusso P, Ratain MJ, Doi T, et al. (2022) Eftozanermin alfa (ABBV-621) monotherapy in patients with previously treated solid tumors: findings of a phase 1, first-in-human study. Investigational New Drugs |
| Lemech C, Woodward N, Chan N, et al. (2020) A first-in-human, phase 1, dose-escalation study of ABBV-176, an antibody-drug conjugate targeting the prolactin receptor, in patients with advanced solid tumors. Investigational New Drugs |
| Nishikawa T, Matsumoto K, Tamura K, et al. (2017) A Phase 1 Dose-Escalation Study of Single-Agent Veliparib in Japanese Patients with Advanced Solid Tumors. Cancer Science |
| Nuthalapati S, Zhou Q, Guo P, et al. (2012) Preclinical pharmacokinetic and pharmacodynamic evaluation of novel anticancer agents, ON01910.Na (Rigosertib, Estybon™) and ON013105, for brain tumor chemotherapy. Pharmaceutical Research. 29: 2499-511 |
| Zhou Q, Guo P, Wang X, et al. (2007) Preclinical pharmacokinetic and pharmacodynamic evaluation of metronomic and conventional temozolomide dosing regimens. The Journal of Pharmacology and Experimental Therapeutics. 321: 265-75 |